{"id":16712,"date":"2026-11-17T06:49:35","date_gmt":"2026-11-17T06:49:35","guid":{"rendered":"https:\/\/financialnewsspot.com\/?p=16712"},"modified":"2026-11-17T06:49:36","modified_gmt":"2026-11-17T06:49:36","slug":"regulatory-review-models-and-approval-timelines-across-african-regulators-chisha-2026","status":"publish","type":"post","link":"https:\/\/financialnewsspot.com\/?p=16712","title":{"rendered":"Regulatory review models and approval timelines across African regulators \u2013 Chisha 2026"},"content":{"rendered":"<div style=\"text-align:center\"><\/div><p> <br \/>\n<\/p>\n<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap\">\n<div class=\"fusion-builder-row fusion-row\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_3_4 3_4 fusion-three-fourth fusion-column-first\" style=\"--awb-bg-size:cover;--awb-margin-bottom:0px;width:74%;margin-right: 4%\">\n<div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\">\n<div class=\"fusion-text fusion-text-1\">\n<p>A new study involving CIRS compares regulatory review models, practices and marketing authorisation timelines across four African national medicines regulatory authorities (NMRAs): Ghana Food and Drugs Authority (Ghana FDA), the Medicines Control Authority of Zimbabwe (MCAZ), the South African Health Products Regulatory Authority (SAHPRA) and the Zambia Medicines Regulatory Authority (ZAMRA).<\/p>\n<p>Published in the <em>British Journal of Clinical Pharmacology<\/em>, the study uses the CIRS <a target=\"_blank\" href=\"https:\/\/cirsci.org\/opera\/\" target=\"_blank\" rel=\"noopener\"><strong>Optimising Efficiencies in Regulatory Agencies (OpERA)<\/strong><\/a> framework to benchmark regulatory performance between 2020 and 2024. It examines approval timelines alongside review pathways, Good Review Practices (GRevPs), quality decision-making practices and other characteristics of the regulatory review process.<\/p>\n<blockquote>\n<p><a target=\"_blank\" href=\"https:\/\/cirsci.org\/download\/chisha-2026-regulatory-review-models-and-approval-timelines-across-african-medicines-regulatory-authorities\/\" target=\"_blank\" rel=\"noopener\">Download the journal article<\/a> to explore the full findings<\/p>\n<\/blockquote>\n<h2>Substantial variation in medicine approval timelines<\/h2>\n<p>The analysis identified substantial variation in marketing authorisation timelines between the four authorities. For new active substances approved in 2024, median approval times ranged from 70 calendar days at Ghana FDA to 1242 days at ZAMRA. Median timelines were 603 days at MCAZ and 628 days at SAHPRA, although application numbers were small at some authorities.<\/p>\n<p>Differences were also observed for generics and biosimilars and at individual stages of the regulatory review process. The findings indicate that longer overall timelines were particularly associated with validation and scientific assessment stages rather than final registration procedures.<\/p>\n<h2>Regulatory maturity alone does not determine approval timelines<\/h2>\n<p>At the time of the study, Ghana FDA, MCAZ and SAHPRA had achieved World Health Organization (WHO) Maturity Level 3 (ML3), while ZAMRA had not. However, substantial variation was also observed between the ML3 authorities, indicating that maturity status alone does not necessarily correspond with shorter total approval timelines.<\/p>\n<p>The research highlights the importance of examining regulatory processes and performance metrics alongside WHO maturity status. Differences in factors such as the types of applications received, regulatory pathways, workflow, applicant response times, staffing and milestone data could contribute to variation, although the study did not test these as causes of the observed differences.<\/p>\n<h2>Opportunities to strengthen regulatory performance<\/h2>\n<p>All four authorities used full, abridged and verification review pathways and had implemented a range of Good Review Practices and quality decision-making approaches. The study identifies opportunities for further regulatory systems strengthening, including greater use of appropriate reliance pathways, digitalisation, increased transparency and continued monitoring of regulatory review practices and approval timelines.<\/p>\n<p>The findings demonstrate how regulatory performance benchmarking can help authorities identify operational bottlenecks and opportunities to improve the efficiency, predictability and transparency of medicines review. This reflects the purpose of CIRS\u2019 OpERA programme, which uses regulatory review process metrics to identify opportunities for optimisation and facilitate cross-agency comparisons.<\/p>\n<h2>About the study<\/h2>\n<p>The research was conducted by the University of the Witwatersrand, ZAMRA, MCAZ, Ghana Food and Drugs Authority, SAHPRA and CIRS. It received an unrestricted grant from the Gates Foundation.<\/p>\n<h2>Citation<\/h2>\n<p>Chisha CS, Leigh S, Siyanga M, et al. <em>Analysis of regulatory review models and approval timelines across selected African medicines regulatory authorities using the OpERA framework (2020\u20132024).<\/em> <em>British Journal of Clinical Pharmacology<\/em>. 2026. DOI: 10.1002\/bcp.70849<\/p>\n<\/div>\n<div class=\"fusion-clearfix\"><\/div>\n<\/div>\n<\/div>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_4 1_4 fusion-one-fourth fusion-column-last\" style=\"--awb-bg-size:cover;width:22%\">\n<div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-column-wrapper-legacy\">\n<div class=\"fusion-image-element fusion-image-align-center in-legacy-container\" style=\"text-align:center;--awb-max-width:800px;--awb-caption-title-font-family:var(--h2_typography-font-family);--awb-caption-title-font-weight:var(--h2_typography-font-weight);--awb-caption-title-font-style:var(--h2_typography-font-style);--awb-caption-title-size:var(--h2_typography-font-size);--awb-caption-title-transform:var(--h2_typography-text-transform);--awb-caption-title-line-height:var(--h2_typography-line-height);--awb-caption-title-letter-spacing:var(--h2_typography-letter-spacing)\">\n<div class=\"imageframe-align-center\"><span class=\" fusion-imageframe imageframe-none imageframe-1 hover-type-none\" style=\"border:1px solid #f6f6f6\"><a target=\"_blank\" class=\"fusion-no-lightbox\" href=\"https:\/\/cirsci.org\/download\/chisha-2026-regulatory-review-models-and-approval-timelines-across-african-medicines-regulatory-authorities\/\" target=\"_blank\" aria-label=\"Chisha 2026 \u2013 Analysis of regulatory review models and approval timelines across African regulators using OpERA \u2013 FRONT COVER\" rel=\"noopener noreferrer\"><\/a><\/span><\/div>\n<\/div>\n<div class=\"fusion-aligncenter\"><a target=\"_blank\" class=\"fusion-button button-flat fusion-button-default-size button-default fusion-button-default button-1 fusion-button-default-span fusion-button-default-type mt-1em\" target=\"_blank\" rel=\"noopener noreferrer\" href=\"https:\/\/cirsci.org\/download\/chisha-2026-regulatory-review-models-and-approval-timelines-across-african-medicines-regulatory-authorities\/?tmstv=1794838472\"><span class=\"fusion-button-text\">Download<\/span><\/a><\/div>\n<div class=\"fusion-clearfix\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/cirsci.org\/publications\/african-medicines-regulatory-approval-timelines\/\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new study involving CIRS compares regulatory review models, practices and marketing authorisation timelines across four African national medicines regulatory authorities (NMRAs): Ghana Food and Drugs Authority (Ghana FDA), the Medicines Control Authority of Zimbabwe (MCAZ), the South African Health Products Regulatory Authority (SAHPRA) and the Zambia Medicines Regulatory Authority (ZAMRA). Published in the British [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":16713,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"tdm_status":"","tdm_grid_status":"","fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[63],"tags":[],"class_list":["post-16712","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health"],"acf":[],"_links":{"self":[{"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/posts\/16712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16712"}],"version-history":[{"count":1,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/posts\/16712\/revisions"}],"predecessor-version":[{"id":16714,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/posts\/16712\/revisions\/16714"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=\/wp\/v2\/media\/16713"}],"wp:attachment":[{"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/financialnewsspot.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}